Twist Bioscience launched its HuTg model to expand antibody discovery services and complement existing in vivo platforms.
1 report, 1 independent
Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Twist Bioscience launched its HuTg model to expand antibody discovery services and complement existing in vivo platforms.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Twist Bioscience
Biotechnology company
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
- VUG concentrates on large-cap leaders like Nvidia. VUG holds large-cap leaders such as Microsoft. VUG holds established giants including Apple. IWO holds small-cap equities including Twist Bioscience.
Coverage
Newest first; wire copies grouped- Business WireTwist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model HuTg can be coupled with Twist hyperimmune DiversimAb mouse model and B cell screening met